Prevalence of Antibodies and Cytokines in Participants with Chronic Granulomatous Disease

Description

This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.

Conditions

Chronic Granulomatous Disease (CGD)

Talk to us

Study Overview

On this page

Study Details

Study overview

This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.

A Cross-Sectional, Observational Study of the Prevalence of Adenoviral-Specific Antibodies and Inflammatory Cytokines in Participants with Chronic Granulomatous Disease

Prevalence of Antibodies and Cytokines in Participants with Chronic Granulomatous Disease

Condition
Chronic Granulomatous Disease (CGD)
Intervention / Treatment

-

Contacts and Locations

Montgomery

Home-based telemedicine, Montgomery, Alabama, United States, 36104

Phoenix

Home-based telemedicine, Phoenix, Arizona, United States, 85001

Little Rock

Home-based telemedicine, Little Rock, Arkansas, United States, 72201

Sacramento

Home-based telemedicine, Sacramento, California, United States, 95814

Denver

Home-based telemedicine, Denver, Colorado, United States, 80202

Hartford

Home-based telemedicine, Hartford, Connecticut, United States, 06103

Dover

Home-based telemedicine, Dover, Delaware, United States, 19901

Washington

Home-based telemedicine, Washington, District of Columbia, United States, 20001

Tallahassee

Home-based telemedicine, Tallahassee, Florida, United States, 32301

Atlanta

Home-based telemedicine, Atlanta, Georgia, United States, 30303

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * The participant must be male.
  • * The participant must have been diagnosed with CGD based on the referring physician's confirmation that nicotinamide adenine diphosphate (NADPH) oxidase activity is \< 1% (i.e., the percentage of dihydrorhodamine-positive \[DHR+\] cells is \< 1% by flow cytometry).
  • * The participant has undergone an allogeneic bone marrow transplant or investigational gene therapy.
  • * The participant is unable to comply with the sample collection procedure based on investigator judgment.

Ages Eligible for Study

to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Ensoma,

Study Record Dates

2025-01